FDA AdCom panel to review and vote on next COVID shots
Source: SeekingAlpha
2026-05-26 11:49:42 ET
More on Pfizer, Moderna, etc.
- Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
- FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
- Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
- BridgeBio downgraded at Raymond James on LOE for Pfizer’s Vyndamax
- Moderna to face FDA AdCom review for flu shot
Read the full article on Seeking Alpha
For further details see:
FDA AdCom panel to review and vote on next COVID shots
Pfizer Inc.
NASDAQ: PFE
PFE Trading
1.14% G/L:
$26.06 Last:
19,233,006 Volume:
$25.85 Open:
PFE Latest News
June 06, 2026 01:52:00 pm
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
June 06, 2026 12:35:00 pm
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
PFE Stock Data
$156,612,814,520
5,628,850,476
0.02%
1712
N/A
Pharmaceuticals
Healthcare
US
New York
